Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

The High Court ruled on a significant patent dispute involving Pfizer and GSK, addressing costs and confidentiality.

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer sold shares of Haleon last year, including a £2.4 billion overnight sale in the autumn. Haleon was formed in 2022 from ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and ...

Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares ...

Pfizer will lower its stake in Haleon from 15 percent to about 7.3% by selling shares worth 2.50 billion pounds ($3.05 ...